Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

Similar articles for PubMed (Select 23115502)

1.

Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth.

Pringsheim T, Panagiotopoulos C, Davidson J, Ho J; Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group.

Paediatr Child Health. 2011 Nov;16(9):581-9.

2.

Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth.

Pringsheim T, Panagiotopoulos C, Davidson J, Ho J; CAMESA guideline group.

J Can Acad Child Adolesc Psychiatry. 2011 Aug;20(3):218-33. Erratum in: J Can Acad Child Adolesc Psychiatry. 2011 August;20(3):1–2..

3.

[Not Available].

Pringsheim T, Panagiotopoulos C, Davidson J, Ho J.

Paediatr Child Health. 2012 Oct;17(Suppl B):12B-21B. French.

4.

Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials.

Pringsheim T, Lam D, Ching H, Patten S.

Drug Saf. 2011 Aug 1;34(8):651-68. doi: 10.2165/11592020-000000000-00000. Review.

PMID:
21751826
5.

Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.

Fraguas D, Correll CU, Merchán-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C.

Eur Neuropsychopharmacol. 2011 Aug;21(8):621-45. doi: 10.1016/j.euroneuro.2010.07.002. Epub 2010 Aug 10. Review.

PMID:
20702068
6.

Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth.

Ho J, Panagiotopoulos C, McCrindle B, Grisaru S, Pringsheim T; CAMESA guideline group.

J Can Acad Child Adolesc Psychiatry. 2011 Aug;20(3):234-41.

7.

The expert consensus guideline series. Treatment of behavioral emergencies 2005.

Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP; Expert Consensus Panel for Behavioral Emergencies 2005.

J Psychiatr Pract. 2005 Nov;11 Suppl 1:5-108; quiz 110-2.

PMID:
16319571
8.
9.

Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth.

Ho J, Panagiotopoulos C, McCrindle B, Grisaru S, Pringsheim T; Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group.

Paediatr Child Health. 2011 Nov;16(9):575-80.

10.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
11.

Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.

Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C.

J Clin Psychopharmacol. 2012 Jun;32(3):309-16. doi: 10.1097/JCP.0b013e3182549259. Review.

PMID:
22544019
12.

Off-label second generation antipsychotics for impulse regulation disorders: a review.

Scheltema Beduin A, de Haan L.

Psychopharmacol Bull. 2010;43(3):45-81. Review.

PMID:
21150846
13.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267
14.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
15.

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.

Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S.

Schizophr Res. 2010 Nov;123(2-3):225-33. doi: 10.1016/j.schres.2010.07.012. Epub 2010 Aug 7. Review.

16.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
17.

Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.

Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS.

Ann Intern Med. 2012 Oct 2;157(7):498-511. Review.

PMID:
22893011
18.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

PMID:
14994733
19.

Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies.

Zuddas A, Zanni R, Usala T.

Eur Neuropsychopharmacol. 2011 Aug;21(8):600-20. doi: 10.1016/j.euroneuro.2011.04.001. Epub 2011 May 6. Review.

PMID:
21550212
20.

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice.

De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU.

Eur Psychiatry. 2011 Apr;26(3):144-58. doi: 10.1016/j.eurpsy.2010.09.011. Epub 2011 Feb 3. Review.

PMID:
21295450
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk